Latest Headlines

Latest Headlines

Generics drag AZ sales down by $1.35B

AstraZeneca's second-quarter results continue the generics-are-woe trend in Big Pharma. This time, it's the antipsychotic drug Seroquel doing most of the damage.

Plavix tops U.S. sales ranks, but not for long

Leave it to a patent expiration to trigger musical chairs at the top of pharma sales rankings. Plavix is now the biggest-selling drug in the U.S., after stealing the crown from Pfizer's newly off-patent Lipitor, PM Live reports.

Ranbaxy reportedly hits bump with Indian regulator

Ranbaxy Laboratories, which is operating under an extensive consent decree with U.S. regulators, has now run afoul of authorities in India.

Lipitor losses lead to Pfizer headcount reduction in Ireland

The generic onslaught on Pfizer's blockbuster Lipitor started just 6 months ago, but the pain is reaching Ireland where the company is poised to cut nearly 200 manufacturing jobs.

Teva says no thank you to generic Lipitor

Teva Pharmaceutical Industries won't be joining the throng of genericsmakers are preparing to flood the market with copycat Lipitor.

Ranbaxy brings in U.S. consultants as part of consent decree

The Indian generics company is bringing in a couple of hired guns to tell it what improvements are left to be made.

Pfizer adds healthy-eating app to Lipitor marketing arsenal

The drugmaker teamed up with EatingWell magazine to develop a mobile app, dubbed Recipes 2 Go, and a sister website, lipitorsmartliving.com. The mobile app hooks into Pfizer's Lipitor co-pay card offer with a feature that makes refills easier.

Rebates cut $40B off drugmakers' returns

In a fascinating look at one aspect of pharma pricing, Forbes' Matthew Herper explores the area of rebates, providing a chart of the biggest givebacks.

With generics horde advancing, Pfizer gives up Lipitor push

When Lipitor's first copycats were unleashed, Pfizer manned the battlements. As The Wall Street Journal reports, that battle is over.

Ranbaxy manufactures a colossal first quarter

Just how important resolving manufacturing problems can be to a drugmaker's upside was evident in the skyrocketing first-quarter earnings of Ranbaxy Laboratories.